- Home
- MYNZ vs ADXN Comparison
MYNZ vs ADXN Comparison
Compare MYNZ & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | ADXN |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | Germany | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 11.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYNZ | ADXN |
|---|---|---|
| Price | $1.06 | $8.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 305.7K | 7.8K |
| Earning Date | 12-29-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $659,935.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $6.51 |
| 52 Week High | $8.20 | $12.05 |
Technical Indicators
Market Signals| Indicator | MYNZ | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 47.77 |
| Support Level | $1.04 | $7.12 |
| Resistance Level | $1.15 | $8.49 |
| Average True Range (ATR) | 0.09 | 0.58 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 39.29 | 52.40 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.